Composition containing tea leaf theanine and assisting in lowering blood pressure and preparation method

Abstract

The invention relates to the technical field of functional food, and particularly discloses a composition containing tea leaf theanine and assisting in lowering blood pressure and a preparation method, the composition comprises the following raw materials in parts by weight: 20-30 parts of a tea leaf theanine chelate, 5-15 parts of a plant extract-phospholipid compound and 55-75 parts of a synergistic matrix; the tea leaf theanine chelate is prepared by carrying out chelation reaction on tea leaf theanine and fermented red algae powder; the plant extract-phospholipid compound is prepared by mixing a grape seed extract, a ginkgo leaf extract and soybean lecithin; the synergistic matrix is prepared by carrying out microsphere embedding on gamma-aminobutyric acid by using resistant dextrin. The tea leaf theanine chelate, the plant extract-phospholipid complex and the synergistic matrix are organically combined, through the synergistic effect, the stability and bioavailability of the core active component are remarkably improved, and the remarkable effects of quick effect taking, long-acting maintenance and synergistic delivery are achieved.

Description

Technical Field

[0001] This invention relates to the field of functional food technology, and more specifically, to a composition containing theanine from tea leaves for assisting in lowering blood pressure and its preparation method. Background Technology

[0002] Hypertension is one of the most common chronic non-communicable diseases worldwide and a leading risk factor for various serious complications such as cardiovascular disease, stroke, and kidney failure. With global socioeconomic development, faster pace of life, changes in dietary structure, and the aging population, the prevalence of hypertension is showing a serious trend of continuous increase and younger onset.

[0003] Currently, clinical treatment of hypertension mainly relies on chemical drugs, such as diuretics, beta-blockers, calcium channel blockers (CCBs), and angiotensin-converting enzyme inhibitors (ACEIs). While these drugs can effectively control blood pressure, they often need to be taken for life, and long-term use may be accompanied by a series of adverse reactions, such as electrolyte imbalances, bradycardia, and metabolic abnormalities. Some patients may also develop drug dependence. Therefore, in addition to conventional drug therapy, seeking safe, effective, low-side-effect, and long-term suitable non-drug interventions is of paramount importance for the comprehensive management of hypertension.

[0004] Chinese Patent Publication No. CN114794478A discloses a composition that can lower blood pressure, blood lipids, and blood sugar. Its core technical solution consists of total saponins from Panax notoginseng, mogrosides, and tea theanine in a weight ratio of 1.5–2.5:0.5–1.5:1.5–2.5. This invention aims to achieve a synergistic effect of lowering blood pressure, blood lipids, and blood sugar through the combination of these three components. Chinese Patent Application Publication No. CN110935002A discloses a composition with blood pressure-lowering effects. Its technical solution is more complex, consisting of up to sixteen raw material components, including soybean peptides, raspberry extract, Rhodiola rosea extract, grape seed extract, green tea extract, and tea theanine. It intends to exert its effects of lowering blood pressure and improving vascular function through a multi-component therapy targeting multiple points. However, after in-depth analysis of the above-mentioned prior art, those skilled in the art have found that the preparation methods of the above-mentioned prior art are all simply physical mixing of each raw material component (extract powder or pure product) with excipients, without taking any technical means to solubilize, promote absorption or protect its stability in the digestive tract. The resulting compositions generally have problems such as poor efficacy, low bioavailability and poor stability.

[0005] In summary, existing technologies merely focus on the formulation and accumulation of natural components with antihypertensive activity, neglecting to address key technical bottlenecks such as inherent synergy, absorption rate, and stability through advanced preparation processes. Based on the above, this invention provides a composition containing theanine from tea leaves for adjuvant antihypertensive effects and a method for its preparation. Summary of the Invention

[0006] To address the problems of insufficient efficacy, low bioavailability, and poor stability in existing blood pressure-lowering compositions containing theanine from tea leaves, this invention provides a composition and preparation method for blood pressure lowering containing theanine from tea leaves. Through the organic combination of multiple technologies such as chelation, phospholipid complexation, and microsphere encapsulation, the bioavailability and stability of each active ingredient are significantly improved, achieving a rapid onset of action, long-lasting effect, and efficient absorption. Compared with the simple physical mixing of existing technologies, it exhibits an unexpected synergistic effect, resulting in a better blood pressure-lowering effect.

[0007] In a first aspect, the present invention provides a composition containing theanine from tea leaves for assisting in lowering blood pressure, employing the following technical solution: A composition containing tea theanine for assisting in lowering blood pressure, comprising the following raw materials in parts by weight: 20-30 parts of tea theanine chelate, 5-15 parts of plant extract-phospholipid complex, and 55-75 parts of synergistic matrix. The tea theanine chelate was prepared by chelating tea theanine with fermented red algae powder. The plant extract-phospholipid complex was prepared by mixing grape seed extract, ginkgo leaf extract and soybean lecithin. The enhancing matrix was prepared by microsphere encapsulation of γ-aminobutyric acid with resistant dextrin.

[0008] Preferably, the tea theanine chelate is prepared by the following method: tea theanine and fermented red algae powder are added to purified water, stirred and dispersed evenly, reacted, and spray-dried to obtain the tea theanine chelate.

[0009] Preferably, the raw materials for preparing the tea theanine chelate are as follows by weight: 10-20 parts of tea theanine, 10 parts of fermented red algae powder, and 180-200 parts of purified water.

[0010] Preferably, in the preparation process of the tea theanine chelate, the stirring speed is 300-500 rpm, the reaction temperature is 45-55℃, and the reaction time is 1.5-2.5 h.

[0011] Preferably, the spray drying parameters are: inlet air temperature 130-150℃, outlet air temperature 80-95℃, and feed rate 5-10L / h.

[0012] Preferably, the fermented red algae powder is prepared by the following method: Red algae powder and liquid culture medium were mixed to obtain a fermentation substrate. Lactobacillus plantarum was inoculated into the fermentation substrate, and anaerobic fermentation was carried out at 33-38℃ and pH 6.5-7.5 for 24-48 hours. After fermentation, the mixture was concentrated and freeze-dried to obtain fermented red algae powder.

[0013] Preferably, the liquid culture medium comprises components glucose, yeast extract, KH2PO4, MgSO4·7H2O, NaCl, and CaCl2.

[0014] Preferably, the liquid culture medium is prepared by the following method: 20.0g glucose, 3.0g yeast extract, 1.5g KH2PO4, 0.5g MgSO4·7H2O, 0.3g NaCl, and 0.1g CaCl2 are dissolved in 800 mL of purified water, heated and stirred until completely dissolved, the pH is adjusted to 6.8±0.2, purified water is added to make up to 1 L, and the mixture is autoclaved at 121℃ for 20 min and then cooled for later use.

[0015] Preferably, the mass ratio of the red algae powder to the liquid culture medium is 1:8-12; and the inoculum amount of *Lactobacillus plantarum* is 3-5%.

[0016] Preferably, the centrifugation temperature of the fermentation broth is 4°C, the centrifugation speed is 5000-7000 rpm, and the centrifugation time is 10-20 min.

[0017] Preferably, the spray drying parameters for the post-washing fermentation broth are: inlet air temperature 130-150℃, outlet air temperature 80-95℃, and feed rate 5-10L / h.

[0018] Preferably, the plant extract-phospholipid complex is prepared by the following method: dissolving grape seed extract and ginkgo leaf extract in anhydrous ethanol, adding soybean lecithin and refluxing, and then distilling under reduced pressure to obtain the plant extract-phospholipid complex.

[0019] Preferably, the raw materials for preparing the plant extract-phospholipid complex are as follows by weight: 2-6 parts grape seed extract, 2-6 parts ginkgo leaf extract, 90-110 parts anhydrous ethanol, and 1-3 parts soybean lecithin.

[0020] Preferably, the reflux reaction parameters are: temperature 55-65℃, time 2-4h.

[0021] Preferably, the vacuum distillation parameters are: vacuum degree -0.07MPa to -0.09MPa, temperature 45-55℃, and time 1-2h.

[0022] Preferably, the synergistic matrix is ​​prepared by the following method: resistant dextrin is dissolved in purified water to form a viscous solution, γ-aminobutyric acid is added and stirred and mixed, and then fluidized bed granulation and coating are performed to obtain the synergistic matrix.

[0023] Preferably, the raw materials for preparing the synergistic matrix are as follows by weight: 45-60 parts resistant dextrin, 140-160 parts purified water, and 10-15 parts γ-aminobutyric acid.

[0024] Preferably, the fluidized bed granulation and coating parameters are: inlet air temperature 65-80℃, material temperature 40-50℃, spray rate 15-25g / min, and atomization pressure 0.15-0.25MPa.

[0025] Preferably, the composition containing theanine from tea leaves for assisting in lowering blood pressure also includes pharmaceutically acceptable excipients.

[0026] Secondly, the present invention provides a method for preparing a composition containing theanine from tea leaves that helps lower blood pressure, using the following technical solution: A method for preparing a composition containing theanine from tea leaves for assisting in lowering blood pressure includes the following steps: By weight, tea theanine chelate, plant extract-phospholipid complex and synergistic matrix are mixed evenly to obtain a composition containing tea theanine for assisting in lowering blood pressure.

[0027] In summary, the present invention has the following beneficial effects: (1) The adjuvant antihypertensive composition containing tea theanine of the present invention achieves a multi-target, multi-pathway adjuvant antihypertensive effect through the synergistic effect of three core active systems. Among them, tea theanine has the effect of regulating the central nervous system and promoting vasodilation. It can reduce the excitability of the sympathetic nerves and improve vascular elasticity by promoting the production of γ-aminobutyric acid and nitric oxide. Moreover, its stability and bioavailability are significantly enhanced after chelation with fermented red algae powder, thereby improving the antihypertensive effect. Grape seed extract and ginkgo leaf extract in the plant extract-phospholipid complex have antioxidant and vasodilatory effects. They can scavenge free radicals, protect endothelial function and inhibit angiotensin-converting enzyme activity. Phospholipid complex technology promotes its intestinal absorption and in vivo stability, and enhances the antihypertensive efficacy of plant active ingredients. γ-aminobutyric acid in the synergistic matrix is ​​released slowly through microsphere encapsulation, and acts stably on vascular smooth muscle and the nervous system, helping to reduce peripheral vascular resistance and heart rate, and ensuring the persistence of the antihypertensive effect. The three work synergistically to significantly improve the adjuvant antihypertensive effect of the composition.

[0028] (2) This invention promotes the optimization of the structure of polysaccharides and minerals in the cell wall of red algae through fermentation, thereby increasing the number of active sites and chelation efficiency of theanine in tea leaves. The theanine in tea leaves is chelated with the polysaccharides and minerals in fermented red algae powder to form a stable theanine chelate. This not only improves the chemical stability of theanine in tea leaves and resists degradation in the processing and gastrointestinal environment, but also promotes the penetration of theanine in tea leaves through the stomach and intestinal walls, thereby improving its oral absorption rate and significantly enhancing its bioavailability.

[0029] (3) This invention uses grape seed extract, ginkgo leaf extract, and soybean lecithin to jointly prepare a plant extract-phospholipid complex. The highly active polyphenols and flavonoids in the grape seed extract and ginkgo leaf extract form a molecularly encapsulated phospholipid complex with soybean lecithin, constructing an affinity bridge between the aqueous and lipid phases, which significantly improves the water solubility and intestinal stability of the active ingredients in the composition. Moreover, the phospholipid complex can mimic the structure of biological membranes, enhance the ability of the active ingredients to penetrate the villi of the small intestine, and play a role in solubilization and transport, effectively improving the absorption efficiency and in vivo half-life of the active ingredients in the composition.

[0030] (4) In this invention, γ-aminobutyric acid is encapsulated in microspheres with resistant dextrin to form a sustained-release targeted delivery system, which protects γ-aminobutyric acid from gastric acid destruction, slows down its release rate, achieves stable release and sustained-release absorption in the intestine, ensures a continuous and effective concentration of active ingredients in the blood, and prolongs the duration of drug efficacy.

[0031] In summary, this invention organically combines tea theanine chelate, plant extract-phospholipid complex, and synergistic matrix. Through synergistic effects, it significantly improves the stability and bioavailability of the core active ingredients, achieving remarkable effects of rapid onset, long-lasting effect, and enhanced delivery. Detailed Implementation

[0032] The present invention will be further described in detail below with reference to the embodiments.

[0033] For experiments not specifically described in the examples, the procedures or conditions should be followed according to the conventional experimental procedures described in the literature in this field. Reagents or instruments whose manufacturers are not specified are all commercially available conventional reagent products.

[0034] The key raw materials used in this invention are sourced from the following sources: Theanine in tea leaves was provided by Hunan Jinong Bioresources Co., Ltd.

[0035] Red algae powder: Model WTHZF1207-1, brand Weite, purchased from Xi'an Weite Biotechnology Co., Ltd.

[0036] Lactobacillus plantarum LP-Onlly: provided by Shanghai Jiaotong University Angli Co., Ltd., strain accession number CGMCCNo.1258.

[0037] Grape seed extract: 10:1 ratio, brand: Waterles Biotechnology, purchased from Lanzhou Waterles Biotechnology Co., Ltd.

[0038] Ginkgo biloba leaf extract: provided by Hunan Jinong Bioresources Co., Ltd.

[0039] Soy lecithin: Brand: Youtai Biotechnology, purchased from Anhui Youtai Biotechnology Co., Ltd.

[0040] Resistant dextrin: Product number CXH2225, brand Hebei Changxinghang, purchased from Hebei Changxinghang Biotechnology Co., Ltd.

[0041] Gamma-aminobutyric acid (GABA): Brand: Yinghe, purchased from Anhui Yinghe Biotechnology Co., Ltd.

[0042] The liquid culture medium was prepared by dissolving 20.0g glucose, 3.0g yeast extract, 1.5g KH2PO4, 0.5g MgSO4·7H2O, 0.3g NaCl, and 0.1g CaCl2 in 800 mL of purified water. The mixture was heated and stirred until completely dissolved. The pH was adjusted to 6.8, and purified water was added to bring the volume to 1 L. The mixture was then autoclaved at 121℃ for 20 min and cooled for later use.

[0043] Fermented red algae powder was prepared by the following method: red algae powder and liquid culture medium were mixed evenly at a mass ratio of 1:10 to obtain fermentation substrate. Lactobacillus plantarum was inoculated into the fermentation substrate at an inoculation amount of 3%. Anaerobic fermentation was carried out at 37℃ and pH 7.0 for 36 hours. After fermentation, the fermentation broth was concentrated through an RO membrane and then freeze-dried to obtain fermented red algae powder.

[0044] Examples 1-3 provide a composition containing theanine from tea leaves for assisting in lowering blood pressure and a method for its preparation.

[0045] Example 1 A composition containing tea theanine for assisting in lowering blood pressure includes the following raw materials in parts by weight: 25 parts of tea theanine chelate, 10 parts of plant extract-phospholipid complex, and 65 parts of synergistic matrix.

[0046] The theanine chelate from tea leaves was prepared by the following method: 15 parts of theanine from tea leaves and 10 parts of fermented red algae powder were added to 190 parts of purified water. The mixture was stirred and dispersed at 400 rpm for 40 min, and then stirred and reacted at 50°C for 2 h. After the reaction was completed, the inlet air temperature was controlled at 140°C, the outlet air temperature at 88°C, and the feed rate at 7.5 L / h, and the mixture was spray-dried to obtain the theanine chelate from tea leaves.

[0047] The plant extract-phospholipid complex was prepared by the following method: 4 parts of grape seed extract and 4 parts of ginkgo leaf extract were dissolved in 100 parts of anhydrous ethanol, and 2 parts of soybean lecithin were added. The mixture was refluxed at 60°C for 3 hours to form a stable molecular-level association. Subsequently, the solvent was removed by vacuum distillation at -0.08 MPa and 50°C for 1.5 hours to obtain the plant extract-phospholipid complex.

[0048] The synergistic matrix was prepared by the following method: 53 parts of resistant dextrin were added to 150 parts of purified water at 75°C and stirred at 650 rpm for 30 min to form a viscous solution. After the viscous solution cooled to 25°C, 12 parts of γ-aminobutyric acid were added and stirred for another 50 min. The inlet air temperature was controlled at 72°C, the material temperature at 45°C, the spray rate at 20 g / min, and the atomization pressure at 0.20 MPa. Fluidized bed granulation and coating were then performed to obtain the synergistic matrix.

[0049] A method for preparing a composition containing theanine from tea leaves for assisting in lowering blood pressure includes the following steps: mixing tea leaf theanine chelate, plant extract-phospholipid complex and synergistic matrix evenly by weight to obtain a composition containing theanine from tea leaves for assisting in lowering blood pressure.

[0050] Example 2 A composition containing tea theanine for assisting in lowering blood pressure includes the following raw materials in parts by weight: 20 parts of tea theanine chelate, 5 parts of plant extract-phospholipid complex, and 75 parts of synergistic matrix.

[0051] The theanine chelate from tea leaves was prepared by the following method: 10 parts of theanine from tea leaves and 10 parts of fermented red algae powder were added to 180 parts of purified water. The mixture was stirred and dispersed at 500 rpm for 30 min, and then stirred and reacted at 55℃ for 1.5 h. After the reaction was completed, the inlet air temperature was controlled at 150℃, the outlet air temperature at 95℃, and the feed rate at 10 L / h, and then spray-dried to obtain the theanine chelate from tea leaves.

[0052] The plant extract-phospholipid complex was prepared by the following method: 2 parts of grape seed extract and 2 parts of ginkgo leaf extract were dissolved in 90 parts of anhydrous ethanol, and 1 part of soybean lecithin was added. The mixture was refluxed at 65°C for 2 hours to form a stable molecular-level association. Subsequently, the solvent was removed by vacuum distillation at -0.09 MPa and 55°C for 2 hours to obtain the plant extract-phospholipid complex.

[0053] The synergistic matrix was prepared by the following method: 60 parts of resistant dextrin were added to 160 parts of purified water at 70°C and stirred at 600 rpm for 40 min to form a viscous solution. After the viscous solution cooled to 30°C, 15 parts of γ-aminobutyric acid were added and the mixture was stirred and mixed for another 60 min. The inlet air temperature was controlled at 80°C, the material temperature at 50°C, the spray rate at 25 g / min, and the atomization pressure at 0.25 MPa. Fluidized bed granulation and coating were then performed to obtain the synergistic matrix.

[0054] A method for preparing a composition containing theanine from tea leaves for assisting in lowering blood pressure includes the following steps: mixing tea leaf theanine chelate, plant extract-phospholipid complex and synergistic matrix evenly by weight to obtain a composition containing theanine from tea leaves for assisting in lowering blood pressure.

[0055] Example 3 A composition containing tea theanine for assisting in lowering blood pressure includes the following raw materials in parts by weight: 30 parts of tea theanine chelate, 15 parts of plant extract-phospholipid complex, and 55 parts of synergistic matrix.

[0056] The theanine chelate from tea leaves was prepared by the following method: 20 parts of theanine from tea leaves and 10 parts of fermented red algae powder were added to 200 parts of purified water. The mixture was stirred and dispersed at 300 rpm for 50 min, and then stirred and reacted at 45°C for 2.5 h. After the reaction was completed, the inlet air temperature was controlled at 130°C, the outlet air temperature at 80°C, and the feed rate at 5 L / h. The mixture was then spray-dried to obtain the theanine chelate from tea leaves.

[0057] The plant extract-phospholipid complex was prepared by the following method: 6 parts of grape seed extract and 6 parts of ginkgo leaf extract were dissolved in 110 parts of anhydrous ethanol, and 3 parts of soybean lecithin were added. The mixture was refluxed at 55°C for 4 hours to form a stable molecular-level association. Subsequently, the solvent was removed by vacuum distillation at -0.07 MPa and 45°C for 2 hours to obtain the plant extract-phospholipid complex.

[0058] The synergistic matrix was prepared by the following method: 45 parts of resistant dextrin were added to 140 parts of purified water at 80°C and stirred at 700 rpm for 20 min to form a viscous solution. After the viscous solution cooled to 20°C, 10 parts of γ-aminobutyric acid were added and stirred for another 40 min. The inlet air temperature was controlled at 65°C, the material temperature at 40°C, the spray rate at 15 g / min, and the atomization pressure at 0.15 MPa. Fluidized bed granulation and coating were then performed to obtain the synergistic matrix.

[0059] A method for preparing a composition containing theanine from tea leaves for assisting in lowering blood pressure includes the following steps: mixing tea leaf theanine chelate, plant extract-phospholipid complex and synergistic matrix evenly by weight to obtain a composition containing theanine from tea leaves for assisting in lowering blood pressure.

[0060] To verify the comprehensive performance of the blood pressure-lowering composition containing theanine from tea provided by the present invention, comparative examples 1-5 were set up, wherein: Comparative Example 1 Comparative Example 1 is the same as Example 1, except that the tea theanine chelate is replaced by a tea theanine mixture prepared by the following method.

[0061] The tea theanine mixture was prepared by the following method: 15 parts of tea theanine and 10 parts of fermented red algae powder were stirred and mixed at 400 rpm for 40 minutes until uniformly mixed to obtain the tea theanine mixture.

[0062] Comparative Example 2 Comparative Example 2 is the same as Example 1, except that the same mass of the plant extract-phospholipid complex is replaced with a mixture of plant extract-phospholipids prepared by the following method.

[0063] The plant extract-phospholipid mixture was prepared by the following method: 4 parts grape seed extract, 4 parts ginkgo leaf extract and 2 parts soybean lecithin were stirred and mixed at 400 rpm for 40 minutes until uniformly mixed to obtain the plant extract-phospholipid mixture.

[0064] Comparative Example 3 Comparative Example 3 is the same as Example 1, except that the preparation method of the plant extract-phospholipid complex is different, as follows: The plant extract-phospholipid complex was prepared by the following method: 8 parts of grape seed extract were dissolved in 100 parts of anhydrous ethanol, and 2 parts of soybean lecithin were added. The mixture was refluxed at 60°C for 3 hours to form a stable molecular-level association. Then, the solvent was removed by vacuum distillation at -0.08 MPa and 50°C for 1.5 hours to obtain the plant extract-phospholipid complex.

[0065] Comparative Example 4 Comparative Example 4 is the same as Example 1, except that the preparation method of the plant extract-phospholipid complex is different, as follows: The plant extract-phospholipid complex is prepared by the following method: Dissolve 8 parts of ginkgo leaf extract in 100 parts of absolute ethanol, add 2 parts of soy lecithin, and reflux and react at a temperature of 60 °C for 3 h to form a stable molecular-level association. Subsequently, control the vacuum degree to -0.08 MPa and the temperature to 50 °C, and distill under reduced pressure for 1.5 h to remove the solvent, obtaining the plant extract-phospholipid complex.

[0066] Comparative Example 5 Comparative Example 5 is the same as Example 1, with the only difference being the preparation method of the synergistic matrix, which is as follows: The synergistic matrix is prepared by the following method: Mix 53 parts of resistant dextrin and 12 parts of γ-aminobutyric acid at a rotation speed of 650 rpm and stir for 50 min until evenly mixed to obtain the synergistic matrix.

[0067] The comprehensive properties of the antihypertensive compositions containing theanine prepared in Examples 1-3 and Comparative Examples l-5 of the present invention were tested respectively.

[0068] I. Verification of antihypertensive effect 1. Experimental animals: Select 50 male spontaneously hypertensive rats (SHR) at 8 weeks of age, and another 5 normal blood pressure rats of the same age Wistar-Kyoto (WKY), with a body weight of 180-220 g, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., and the experimental animal production license number: SCXK (Beijing) 2021-0006.

[0069] 2. Group experiments: After 7 days of adaptive feeding, randomly divide the spontaneously hypertensive rats into 10 groups, with 5 rats in each group, and record them as follows: model group, positive control group, Example 1-3 groups, and Comparative Example 1-5 groups; record the 5 normal blood pressure rats as the blank group. Among them, in the Example 1-3 groups and Comparative Example 1-5 groups, the composition was formulated into a suspension (the mass ratio of the composition to normal saline is 1:4), and intragastric administration was carried out at a dose of 100 mg / kg body weight; the positive control group was administered irbesartan at a dose of 15 mg / kg body weight. All were continuously administered for 8 weeks, once a day, and the blank group and the model group were intragastrically given an equal volume of normal saline every day.

[0070] 3. Blood pressure measurement 2 h after the last administration, the non-invasive tail artery blood pressure measurement method (BP-2010A type animal blood pressure measuring instrument, Ruanlong Technology) was used to measure the blood pressure of each group of rats before administration (week 0) and after administration (week 8).

[0071] 4. All test data are expressed as mean and standard deviation, and the data are processed using SPSS13.0 software. The results are shown in Table 1 below.

[0072] Table 1: Blood pressure measurement results (mmHg, n = 10, )

[0073] Note: Compared with the normal control group, , , ,

[0079] , , , P < 0.05, ** P < 0.01; compared with the model control group, # P < 0.05, ## P < 0.01.

[0074] As can be seen from the results shown in Table 1: The antihypertensive effects of Examples 1 - 3 of the present invention are significantly better than those of Comparative Examples 1 - 5.

[0075] II. Bioavailability verification (rat pharmacokinetic experiment) 1. Experimental animals: Twenty-five 8-week-old healthy male SD rats with a body weight of 180 - 220 g were selected, purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd., and the experimental animal production license number: SCXK (Beijing) 2021 - 0006.

[0076] 2. Group experiment: After 7 days of adaptive feeding, they were randomly divided into 5 groups, with 5 rats in each group, and were respectively denoted as Example 1 and Comparative Examples 1 - 4 groups.

[0077] 3. Administration and blood collection: Fast for 12 h before administration and allow free access to water. After fasting, a single intragastric administration of an equivalent dose of the composition (15 mg / kg body weight calculated by theanine) was given; 0.3 mL of blood was collected from the orbital venous plexus at 0.25 h, 0.5 h, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, and 24 h after administration into heparin anticoagulant tubes, centrifuged at 4°C and 3000 rpm for 10 min to separate plasma, and the plasma samples were stored at -20°C.

[0078] 4. Sample processing and detection After the plasma samples were precipitated with methanol to remove proteins, the concentrations of theanine and procyanidin B2 (grape seed marker) and ginkgolide B (ginkgo leaf marker) were determined by UPLC-MS / MS. <​​​​​​​​Key parameters: peak concentration (Cmax), time to peak (Tmax), area under the curve (AUC0-24h), mean residence time (MRT). The results are shown in Table 2-4 below.

[0080] Table 2: Pharmacokinetic parameters of theanine in tea (n=10, )

[0081] Note: Comparative Example 1 is set as the baseline group, with a relative bioavailability of 100%.

[0082] Table 3: Pharmacokinetic parameters of proanthocyanidin B2 (n=10, )

[0083] Note: Comparative Example 2 is set as the baseline group, with a relative bioavailability of 100%.

[0084] Table 4: Pharmacokinetic parameters of Ginkgolide B (n=10, )

[0085] Note: Comparative Example 2 is set as the baseline group, with a relative bioavailability of 100%.

[0086] As shown in Tables 2-4, the relative bioavailability of theanine in tea leaves in Example 1 was 82.7% higher than that of Comparative Example 1 without chelation (P<0.01); the relative bioavailability of proanthocyanidin B2 in Example 1 was 228.5% higher than that of Comparative Example 2 without phospholipid complex preparation, and the bioavailability of ginkgolide B was increased by 215.2% (P<0.01); the bioavailability increases of Comparative Example 3 (grape seed and phospholipid complex only) and Comparative Example 4 (ginkgo leaf and phospholipid complex only) were lower than those of Example 1, which contained two plant extracts, demonstrating the advantages of synergistic compounding of two plant extracts.

[0087] This specific embodiment is merely an explanation of the present invention and is not intended to limit the invention. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they are within the scope of the claims of the present invention.

Claims

1. A composition containing theanine from tea leaves for assisting in lowering blood pressure, characterized in that, The ingredients include the following parts by weight: 20-30 parts of tea theanine chelate, 5-15 parts of plant extract-phospholipid complex, and 55-75 parts of synergistic matrix; The tea theanine chelate was prepared by chelating tea theanine with fermented red algae powder. The plant extract-phospholipid complex was prepared by mixing grape seed extract, ginkgo leaf extract and soybean lecithin. The enhancing matrix was prepared by microsphere encapsulation of γ-aminobutyric acid with resistant dextrin.

2. The composition for assisting in lowering blood pressure containing theanine from tea leaves according to claim 1, characterized in that, The theanine chelate from tea leaves was prepared by the following method: tea theanine and fermented red algae powder were added to purified water, stirred and dispersed evenly, and then reacted and spray-dried to obtain the theanine chelate from tea leaves.

3. The composition for assisting in lowering blood pressure containing theanine from tea, as described in claim 2, is characterized in that... The raw materials for preparing the tea theanine chelate are as follows by weight: 10-20 parts tea theanine, 10 parts fermented red algae powder, and 180-200 parts purified water.

4. The composition for assisting in lowering blood pressure containing theanine from tea, as described in claim 2, is characterized in that... The fermented red algae powder is prepared by the following method: Red algae powder and liquid culture medium were mixed to obtain a fermentation substrate. Lactobacillus plantarum was inoculated into the fermentation substrate and anaerobic fermentation was carried out at 33-38℃ and pH 6.5-7.5 for 24-48 hours. After fermentation, the fermentation broth was concentrated and freeze-dried to obtain fermented red algae powder.

5. The composition for assisting in lowering blood pressure containing theanine from tea, as described in claim 4, is characterized in that... The liquid culture medium contains components including glucose, yeast extract, KH2PO4, MgSO4·7H2O, NaCl, and CaCl2.

6. The composition for assisting in lowering blood pressure containing theanine from tea leaves according to claim 1, characterized in that, The plant extract-phospholipid complex was prepared by the following method: grape seed extract and ginkgo leaf extract were dissolved in anhydrous ethanol, soybean lecithin was added and refluxed, and the plant extract-phospholipid complex was obtained by vacuum distillation.

7. The composition for assisting in lowering blood pressure containing theanine from tea, as described in claim 6, is characterized in that... The raw materials for preparing the plant extract-phospholipid complex are as follows by weight: 2-6 parts grape seed extract, 2-6 parts ginkgo leaf extract, 90-110 parts anhydrous ethanol, and 1-3 parts soybean lecithin.

8. The composition for assisting in lowering blood pressure containing theanine from tea, as described in claim 1, is characterized in that, The synergistic matrix is ​​prepared by the following method: resistant dextrin is dissolved in purified water to form a viscous solution, γ-aminobutyric acid is added and stirred and mixed, and then fluidized bed granulation and coating are performed to obtain the synergistic matrix.

9. The composition for assisting in lowering blood pressure containing theanine from tea leaves according to claim 8, characterized in that, The raw materials for preparing the synergistic matrix are as follows by weight: 45-60 parts resistant dextrin, 140-160 parts purified water, and 10-15 parts γ-aminobutyric acid.

10. A method for preparing a composition containing theanine from tea leaves for assisting in lowering blood pressure, as described in any one of claims 1-9, characterized in that, Includes the following steps: By weight, tea theanine chelate, plant extract-phospholipid complex and synergistic matrix are mixed evenly to obtain a composition containing tea theanine for assisting in lowering blood pressure.

Images